A clinical investigator from the University of Kansas School of Medicine, Patrick M. Moriarty, co-led a clinical trial testing a drug focusing on individuals who have inherited a condition subjecting them to high cholesterol irrespective of diet or lifestyle. The...
As reported in West Globe Newswire, Novartis has announced its’ move into developing a targeted cardiovascular therapy by exercising an option to license the rights to develop and commercialize TQJ230, an investigational agent preciously known as AKCEA-APO(a)-LRx,...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
